Currently, there are 64.58M common shares owned by the public and among those 47.96M shares have been available to trade.
The company’s stock has a 5-day price change of 19.69% and 27.55% over the past three months. TERN shares are trading 40.52% year to date (YTD), with the 12-month market performance up to 74.38% higher. It has a 12-month low price of $3.26 and touched a high of $10.03 over the same period. TERN has an average intraday trading volume of 1.20 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 22.52%, 17.73%, and 38.78% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Terns Pharmaceuticals Inc (NASDAQ: TERN) shares accounts for 71.43% of the company’s 64.58M shares outstanding.
It has a market capitalization of $641.77M and a beta (3y monthly) value of -0.38. The earnings-per-share (ttm) stands at -$1.31. Price movements for the stock have been influenced by the stock’s volatility, which stands at 12.08% over the week and 8.17% over the month.
Earnings per share for the fiscal year are expected to decrease by -1.17%, and -7.34% over the next financial year.
Looking at the support for the TERN, a number of firms have released research notes about the stock. Mizuho stated their Buy rating for the stock in a research note on June 22, 2023, with the firm’s price target at $16. Jefferies coverage for the Terns Pharmaceuticals Inc (TERN) stock in a research note released on June 07, 2023 offered a Buy rating with a price target of $18. ROTH MKM was of a view on May 31, 2023 that the stock is Buy, while BMO Capital Markets gave the stock Outperform rating on May 08, 2023, issuing a price target of $18. JMP Securities on their part issued Mkt Outperform rating on February 14, 2023.
